Table 3.
Patient demographics and baseline disease characteristics: DMF-to-DRF subgroup
| Patient demographics and baseline characteristics | DMF-to-DRF subgroup (N = 26) |
|---|---|
| Age, years | |
| Median (range) | 51 (35–79) |
| Age < 55 years | 14 (53.8) |
| Age ≥ 55 years | 12 (46.2) |
| Female | 22 (84.6) |
| MS diagnosis | |
| Confirmed by ICD-10 code for MS | 22 (84.6) |
| Inferred by drug therapy classification of MS | 4 (15.4) |
| US regiona | |
| Northeast | 1 (3.8) |
| Midwest | 8 (30.8) |
| South | 6 (23.1) |
| West | 11 (42.3) |
| Reason for discontinuing prior DMF therapy | |
| Known reason | 15 (57.7) |
| GI AE | 13 (86.7) |
| Other AEb | 2 (13.3) |
| Unknown reason | 11 (42.3) |
| Prior DMF treatment duration, months, median (range) | 7.2 (0.2–56.5) |
| DRF treatment duration, months, median (range) | 6.8 (1.0–8.4) |
All values reported as n with the percentage in parenthesis, unless otherwise indicated
AE adverse event, DRF diroximel fumarate, GI gastrointestinal, ICD-10 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, MS multiple sclerosis
aRegional breakdown based on 2020 US Census categories for region
bOne patient reported acne as the AE leading to discontinuation, and 1 patient reported flushing/flushing-related events